Form 4: Bolt Biotherapeutics Director Laura Berner Receives Stock Option Grant Post-Reverse Split

Bolt Biotherapeutics Director Laura Berner was granted 1,100 stock options at an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Summary

• Laura Berner, a Director of Bolt Biotherapeutics, Inc. (BOLT), acquired stock options on May 27, 2025.
• A 1-for-20 reverse stock split of common stock was effected by the Company on June 6, 2025.
• The reporting person was granted options to purchase 1,100 shares of common stock at an exercise price of $6.4 per share, with all reported share and exercise price amounts reflecting the reverse stock split.
• Prior to the reverse stock split, the grant was for 22,000 shares at an exercise price of $0.32 per share.
• The options will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service.
• Full vesting of the options will occur upon a change in control of the Issuer.
• The stock options are exercisable until their expiration date of May 26, 2035.
• Following this reported transaction, Laura Berner beneficially owns 1,100 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine stock option grant to an existing director, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. The context of a prior reverse stock split is noted but not elaborated upon in terms of its impact on company performance or outlook within this specific document.

Positives

• The grant of stock options to Director Laura Berner aligns her financial interests with the long-term performance and shareholder value of Bolt Biotherapeutics.
• The options have a long expiration date of May 26, 2035, providing a substantial window for potential value realization.
• The provision for full vesting upon a change in control could incentivize strategic transactions that may benefit shareholders.

Negatives

• No specific negatives are presented regarding the stock option grant itself within this filing.

Risks

• Vesting of the stock options is contingent upon the reporting person's continuous service through the specified vesting date.
• The value of the stock options is dependent on the future market price of Bolt Biotherapeutics' common stock exceeding the $6.4 exercise price.

Future Outlook

The stock options are scheduled to vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, provided continuous service is maintained. Additionally, full vesting will occur upon a change in control of the Issuer.

Industry Context

This Form 4 filing reports an individual insider transaction and does not contain information related to broader industry trends or competitors.

Related Party Transactions

• Grant of stock options to Laura Berner, a Director of Bolt Biotherapeutics, Inc., as part of her compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align management's interests with shareholder value creation, as the options gain value if the stock price increases above the exercise price.
• Employees: No direct impact on general employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• Vesting of the granted stock options on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, subject to continuous service.
• Potential full vesting of the options upon a change in control of Bolt Biotherapeutics, Inc.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Insider Transaction, Stock Option, Director Compensation, Equity Grant, Reverse Stock Split, Beneficial Ownership